EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)Multizentrische StudieOpen Access · CC BY 4.0

Effective long‐term prophylaxis with lanadelumab in adolescents with hereditary angioedema: EMPOWER / ENABLE

Raffi Tachdjian, Aleena Banerji, Paula J Busse, Nancy Agmon-Levin, John Anderson, Mauro Cancian iD, Giuseppe Spadaro, Carmen Enciu, Daniel Nova Estepan, Natalie Khutoryansky, Siddharth Jain, Andreas Recke

Pediatric Allergy and Immunology · 2025

DOI: 10.1111/pai.70072 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift Pediatric Allergy and Immunology, 2025. Verfasst von Raffi Tachdjian und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy, Immunology and Rheumatology, UCLA School of Medicine, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Angioedemas, Hereditary, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Development Center Americas, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Symptoms of hereditary angioedema (HAE) typically first present during childhood, but the frequency/severity of attacks often increases at puberty. Real‐world data on long‐term HAE prophylaxis in adolescents are limited. We report pooled data from adolescent patients enrolled in two Phase 4 studies (EMPOWER, ENABLE) evaluating the effectiveness/safety of lanadelumab (monoclonal antibody directed against plasma kallikrein) for the prevention of HAE attacks.

Methods

Adolescent patients (aged 12 to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angioedemas, HereditaryAntibodies, Monoclonal, HumanizedAdolescentChildFemaleHumansMaleTreatment OutcomeProspective Studies

Stichwörter der Autor:innen

adolescentseffectivenesshereditary angioedemalanadelumabprophylaxissafety

Substanzen

Antibodies, Monoclonal, Humanizedlanadelumab

Autor:innen und Institutionen

  • Division of Allergy, Immunology and Rheumatology, UCLA School of Medicine, Los Angeles, California, USA.
  • Providence St. John Medical Center, Santa Monica, California, USA.
  • Division of Rheumatology, Allergy and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Division of Allergy and Clinical Immunology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Clinical Immunology, Angioedema and Allergy Institute, The Center for Autoimmune Diseases, Sheba Medical Center, Tel HaShomer Hospital, Ramat-Gan, Israel.
  • AllerVie Health, Birmingham, Alabama, USA.

ORCID-Profile: Mauro Cancian

Förderung

  • Takeda Development Center Americas, Inc

Zitieren

APA

Tachdjian, R., Banerji, A., Busse, P. J., Agmon-Levin, N., Anderson, J., Cancian, M., Spadaro, G., Enciu, C., Estepan, D. N., Khutoryansky, N., Jain, S., & Recke, A. (2025). Effective long‐term prophylaxis with lanadelumab in adolescents with hereditary angioedema: EMPOWER / ENABLE. Pediatric Allergy and Immunology. https://doi.org/10.1111/pai.70072

Vancouver

Tachdjian R, Banerji A, Busse PJ, Agmon-Levin N, Anderson J, Cancian M, et al. Effective long‐term prophylaxis with lanadelumab in adolescents with hereditary angioedema: EMPOWER / ENABLE. Pediatric Allergy and Immunology. 2025. doi:10.1111/pai.70072

BibTeX
@article{Tachdjian2025,
  author = {Tachdjian, Raffi and Banerji, Aleena and Busse, Paula J and Agmon-Levin, Nancy and Anderson, John and Cancian, Mauro and Spadaro, Giuseppe and Enciu, Carmen and Estepan, Daniel Nova and Khutoryansky, Natalie and Jain, Siddharth and Recke, Andreas},
  title = {Effective long‐term prophylaxis with lanadelumab in adolescents with hereditary angioedema: EMPOWER / ENABLE},
  journal = {Pediatric Allergy and Immunology},
  year = {2025},
  doi = {10.1111/pai.70072}
}
Kostenlos starten →